ResMed (RMD) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- US stock futures muted as oil holds near April highs ahead of Fed decision
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $253.20 --0%
EPS Growth %: +5.1%
Financial Fact:
Net income: 76.11M
Today's EPS Names:
OMID, SICP, SCKT, More
EPS Growth %: +5.1%
Financial Fact:
Net income: 76.11M
Today's EPS Names:
OMID, SICP, SCKT, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q2 EPS of $0.69, $0.03 better than the analyst estimate of $0.66. Revenue for the quarter came in at $454.5 million versus the consensus estimate of $446.25 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- S&P Global (SPGI) Tops Q3 EPS by 16c
- Corning (GLW) Tops Q3 EPS by 3c; offers guidance
- SoFi Technologies (SOFI) Tops Q3 EPS by 1c, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
